title: Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients.
abstract: OBJECTIVE
  To evaluate 24-hour intraocular pressure (IOP) efficacy of latanoprost versus travoprost, each given every evening, in exfoliative glaucoma patients.
  
  
  METHODS
  Prospective, observer-masked, crossover comparison.
  
  
  METHODS
  Forty patients with exfoliation glaucoma.
  
  
  METHODS
  Patients with a pressure of >24 mmHg were randomized to latanoprost or travoprost for an 8-week treatment period after a 6-week medicine-free period. Patients were then switched to the opposite treatment for the second period. At untreated baseline and at the end of each treatment period the IOP was measured at 6 am, 10 am, 2 pm, 6 pm, 10 pm, and 2 am.
  
  
  METHODS
  Diurnal IOP.
  
  
  RESULTS
  The mean 24-hour IOP was 25.1+/-2.5 mmHg at baseline, 17.8+/-2.1 mmHg on latanoprost, and 17.3+/-2.2 mmHg on travoprost (P = 0.001). Individual time points were similar between treatments, except at 6 pm when travoprost provided lower IOP (16.7+/-2.6 vs 17.9+/-2.5 mmHg, P<0.001). Adverse events showed more conjunctival hyperemia with travoprost (n = 15) than latanoprost (n = 6; P = 0.03).
  
  
  CONCLUSIONS
  Latanoprost and travoprost both significantly reduce the 24-hour IOP from baseline in exfoliative glaucoma, but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon.
authors.affiliation: Glaucoma Unit, Department of Ophthalmology, A University, Thessaloniki, Greece.
authors.forename: Anastasios G P
authors.initials: AG
authors.lastname: Konstas
authors.forename: Vassilios P
authors.initials: VP
authors.lastname: Kozobolis
authors.forename: Ioannis E
authors.initials: IE
authors.lastname: Katsimpris
authors.forename: Kostantinos
authors.initials: K
authors.lastname: Boboridis
authors.forename: Stavrenia
authors.initials: S
authors.lastname: Koukoula
authors.forename: Jessica N
authors.initials: JN
authors.lastname: Jenkins
authors.forename: William C
authors.initials: WC
authors.lastname: Stewart
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002940:Circadian Rhythm; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D017889:Exfoliation Syndrome / Q000188:drug therapy*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D000069557:Travoprost; D016896:Treatment Outcome; D014792:Visual Acuity; D014794:Visual Fields
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069557:Travoprost